Identification of novel targets for immunotherapies in subsets of patients with diffuse large B-cell lymphoma (DLBCL).

Heini, Alexander D; Bacher, Ulrike; Pabst, Thomas

Heini, Alexander D; Bacher, Ulrike; Pabst, Thomas.

Afiliación

Heini AD; Department of Medical Oncology, Inselspital, Bern University Hospital, Bern, Switzerland.
Bacher U; Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, Bern, Switzerland.
Pabst T; Department of Medical Oncology, Inselspital, Bern University Hospital, Bern, Switzerland.

Br J Haematol ; 204(2): 389-390, 2024 02.

Article en En | MEDLINE | ID: mdl-37964473

RESUMEN

Personalized treatment options for subsets of patients with DLBCL are beginning to emerge. Caracciolo et al. explore UMG1, an epitope of CD43 as a potential target for certain patients with DLBCL, and demonstrate promising preclinical activity of an Anti-UMG1-antibody. Commentary on: Caracciolo et al. UMG1/CD3Îµ-bispecific T-cell engager (BTCE) redirects T-cell cytotoxicity against diffuse large B-cell lymphoma (DLBCL). Br J Haematol 2024;204:555-560.

Asunto(s)

Linfoma de Células B Grandes Difuso; Humanos; Linfoma de Células B Grandes Difuso/patología; Inmunoterapia; Linfocitos T

Palabras clave

DLBCL; UMG1; bispecific T-cell engager; personalized medicine

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Linfoma de Células B Grandes Difuso Límite: Humans Idioma: En Revista: Br J Haematol Año: 2024 Tipo del documento: Article País de afiliación: Suiza

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google